Persistent demyelination, in addition to being the major pathology of multiple sclerosis and the leucodystrophies, is also a feature of spinal cord trauma where there is evidence that it contributes to the functional deficit. In experimental animals it is possible to remyelinate demyelinated CNS axons by transplanting cultures containing central or peripheral myelinogenic cells. Using functional testing we have been able to show that transplant-mediated remyelination results in restoration of function lost as a consequence of demyelination. Glial cell transplantation may therefore provide a therapeutic strategy for remyelinating areas of chronic demyelination. This article reviews issues that have to be addressed before glial transplantation can be undertaken in humans. These include: what cells to use, where would the cells come from, and can we predict how much remyelination will be achieved? It concludes that the most promising approach will be to use neural multipotential stem cells isolated from embryonic CNS, expanded in vitro as neurospheres and then committed to oligodendrocyte lineage differentiation prior to implantation. However, even with such preparations, which have considerable myelinating potential, the extent of remyelination that will be achieved cannot currently be predicted with any degree of certainty.
INTRODUCTION
Persistent demyelination, in addition to being the ma jor pathology of multiple sclerosis and the leucodystrophies, is also a feature of spinal cord trauma where there is evidence that it contributes to the functional deficit (11, 36) . In experimental animals it is possible to remy elinate demyelinated CNS axons by transplanting cul tures containing central or peripheral myelinogenic cells (8) . Myelin sheaths made by transplanted glial cells en hance action potential conduction (20, 21, 39) and we have been able to show that both normal and transplantmediated remyelination results in restoration of function lost as a consequence of demyelination (22) . In addition, Schwann cell and olfactory ensheathing cell transplanta tion, in the form of "bridges," provides a means of stim ulating regeneration of CNS axons (19, 32) . Glial cell transplantation may therefore provide a therapeutic strat egy for remyelinating areas of chronic demyelination and stimulating axon regeneration. However, before glial transplantation can be undertaken in humans as a treatment in situations where endogenous remyelination has failed, a number of issues have to be resolved. The most important of these are: will the procedure be safe, and will it be effective in restoring function lost as a consequence of chronic demyelination?
WILL INTRODUCTION OF GLIAL CELLS INTO AREAS OF DEMYELINATION BE SAFE?
The experience gained from human and xenogenic tissue grafting for the treatment of Parkinson's disease indicates that the introduction of exogenous cells into the human brain is not an inherently hazardous proce dure providing donor tissue is monitored for potentially harmful pathogens. It has been our experience that the injections of suspensions of glial cells into areas of acute demyelination does not damage axons provided the sus pensions do not have very high numbers of astrocytes and that they contain some cells that have the capacity to generate myelin sheaths (unpublished observations). The injection of embryonic tissue that has the potential to generate neurons leads to the development of classical neural grafts that can act as space-occupying lesions in the context of white matter tracts (unpublished observa tions). However, if the transplant is prepared in such a way that avoids this outcome then injection of myelino genic cells would appear to be a sufficiently safe proce-dure to proceed to clinical trials that primarily involve assessment of safety and also the feasibility of detecting remyelination (Phase I clinical trials).
A central issue to be addressed prior to such clinical trials is whether transplanted glial cells are able to remy elinate large areas of demyelination. In order to resolve this issue we need to know the answers to three related questions: what cells to use, where would the cells come from, and can we predict how much remyelination there will be following the introduction different types of cells?
WHAT CELLS WOULD BE MOST APPROPRIATE TO TRANSPLANT?
The This last observation was to be expected given the greater capacity for division and migration of the imma ture cell in vitro (31) . Recent data suggest that cells ear lier in the oligodendrocyte lineage than the A2B5+ pro genitor may have an even greater capacity for extensive transplantation-derived remyelination (2, 12, 23, 43) .
Self-renewing multipotential neural stem cells that can differentiate into neurons, astrocytes, and oligoden drocytes can be isolated from both the embryonic and adult rodent brain and can be expanded in vitro as clus ters of cells in serum-free medium containing EGF or FGF-2. A more restricted differentiation develops when these multipotential neural stem cell clusters are ex panded under the influence of medium conditioned by the B104 neuroblastoma cell line (2, 43) . Such clusters are termed oligospheres, and it is significant that implan tation of oligospheres into the spinal cord of the myelin-deficient rat results in larger areas of myelination than implantation of neurospheres (26, 42) .
AVAILABILITY OF HUMAN MYELINOGENIC CELLS
Although oligodendrocytes can be obtained from the adult human CNS in relatively large numbers, these cells fail to generate myelin sheaths when transplanted into demyelinated rat CNS (38) . On the other hand, implan tation of fetal human CNS tissue into the developing rodent brain results in the generation of myelinationcompetent cells (35) . Until recently, this implied that if glial cell transplantation using CNS cells was to be de 
REMYELINATING CAPACITY OF DIFFERENT CELL TYPES
To date most transplantation studies have been con planted cells will have to migrate widely. Our ability to predict whether this will be achieved depends on the cell type to be used. In the case of Schwann cells we can predict that myelination will be limited for reasons dis cussed in the next section. However, the extent of remy elination that may be achieved following the introduc tion of oligodendrocyte progenitors is more difficult to predict because of our incomplete knowledge of CNS remyelination and limitations imposed by the models currently used for transplantation experiments.
Remyelination by Transplanted Schwann Cells
Schwann cells myelinate CNS axons most exten sively when there is a combination of disruption of the glia limitans and the presence of axon that should be myelinated (16) . 
Remyelination by Transplanted Oligodendrocyte Lineage Cells
Most of the studies that have demonstrated the oligodendrocyte-generating potential of mutipotential neural stem cells and extensive migration of transplanted my elinogenic cells have been conducted in the immature nervous system. It is clear from our own work that pro genitor cells behave very differently when introduced into the adult CNS. Thus, despite their capacity to mi grate in vitro, during development and after implantation into the developing nervous system, supernumerary oli godendrocyte progenitors do not survive following im plantation into normal adult white matter and are there-fore unable to migrate (15, 30) . They do, however, sur vive and differentiate into oligodendrocytes when im planted into areas of demyelination and will migrate in normal white matter if it has been subjected to doses of x-irradiation sufficient to deplete the tissue of endogenous precursors (15, 24, 30) . This latter observation demon strates that although the adult CNS cannot support oligo dendrocyte progenitor survival and migration in its native state, it is amenable to modification to enable it to do so.
Although numerous studies have now shown that This lack of data is important, as it is now clear from studies on endogenous remyelination that, contrary to our previous understanding, remyelination can be a pro tracted process (18, 37, 42 (14) , can influence process formation by oligodendrocytes (27) , and in some experiments actu ally inhibit myelination by reducing oligodendrocyte numbers (33) . Thus, despite the knowledge that one can remyelinate areas of demyelination and restore function by transplantation, and that the cells with the greatest remyelinating potential are cells at the pre-oligodendrocyte progenitor stage of development, we lack the quan titative information that would allow us to predict the extent of remyelination that might be achieved following transplantation of a given number of cells of a particular phenotype into an area of chronic demyelination. How ever, exciting results from Ian Duncan's laboratory indi cate that when the right cells are used and animals are allowed to survive long enough remyelination can be very extensive (1) .
PROSPECTS FOR CLINICAL APPLICATION
The recent progress with human multipotential neural stem cells means that human therapy would not require excessive amounts of human embryonic tissue. Al though it may take some time to define the in vitro con ditions necessary to obtain oligodendrocyte pre-progenitors from human multipotential neural stem cells, serious consideration should be given to the practicali ties of clinical trails.
